Gaba-A Receptor Modulation: Novel Pharmacological Strategies for Anxiety Disorders

Anxiety disorders represent a significant mental health concern worldwide, characterised by excessive apprehension, persistent fear, physiological disturbances, and reduced daily functioning. The gamma-aminobutyric acid type A (GABA-A) receptor system plays a crucial role in regulating neuronal activity and maintaining inhibitory neurotransmission within the central nervous system. Owing to its involvement in controlling neuronal excitability, this receptor complex has become an important target for the development of anxiolytic medications.Several pharmacological agents, including benzodiazepines, neuroactive steroids, and positive allosteric modulators, exert their effects by influencing GABA-A receptor activity. Despite their rapid therapeutic action, conventional benzodiazepines are associated with adverse effects such as drowsiness, impaired coordination, tolerance, physical dependence, and withdrawal complications. These limitations have encouraged investigations into alternative therapeutic approaches, including receptor-subtype-selective compounds, ligands targeting distinct allosteric sites, and neurosteroid-based interventions. This review examines the structural characteristics and functional properties of GABA-A receptors, their contribution to the pathophysiology of anxiety, the pharmacological mechanisms of established anxiolytic agents, and recent developments in receptor-targeted drug discovery. It also highlights the challenges involved in translating experimental findings into effective clinical treatments. Further investigation of receptor-subunit composition and ligand-binding mechanisms may facilitate the identification of safer and more selective anxiolytic agents. Nevertheless, additional clinical studies are required to establish the therapeutic efficacy, tolerability, and long-term safety of emerging treatment strategies.[1]